Gri Bio Operations, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2009-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.gribio.com
Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (100.0%)Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients with IPF
Phase 2
Recruiting
- Conditions
- Idiopathic Pulmonary FibrosisIPF
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- GRI Bio Operations, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06331624
- Locations
- 🇺🇸
Newport Native MD, Inc., Newport Beach, California, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease
Phase 2
Terminated
- Conditions
- Chronic Liver Disease
- Interventions
- Drug: Placebo Comparator
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- GRI Bio Operations, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT02949375
- Locations
- 🇿🇦
Steve Biko Academic Hospital, Pretoria, Gauteng, South Africa
News
No news found